MedTrace Logo

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer

NCT04994795 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2024-11-21

No results posted yet for this study

Summary

Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.

Conditions

  • Non-small Cell Lung Cancer Metastatic

Interventions

OTHER

Predictive models (data collection)

Machine learning predictive models

Sponsors & Collaborators

  • Sophia Genetics SAS

    lead INDUSTRY

Principal Investigators

  • Philippe Menu, MD-PhD, MBA · SOPHiA GENETICS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-21
Primary Completion
2024-12-31
Completion
2025-02-28

Countries

  • United States
  • Brazil
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04994795 on ClinicalTrials.gov